Eurofins-Cerep SA AI Stock Analysis
Eurofins-Cerep SA (ALECR) AI Stock Analysis
Eurofins-Cerep SA
(Paris:ALECR)
No summary available
Eurofins-Cerep SA (ALECR) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 75.67M
- Dividend Yield
- ―
- Average Volume (3M)
- 1
- Price to Earnings (P/E)
- 17.0
- Beta (1Y)
- -0.06
- Revenue Growth
- 1.28%
- EPS Growth
- -33.15%
- Country
- France
- Employees
- 209
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Diagnostics & Research
Eurofins-Cerep SA Business Overview & Revenue Model
Company Description
Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the managemen...
Eurofins-Cerep SA Peers Comparison
Overall Rating
FR:BIM73Outperform
FR:ALERS58Neutral
FR:ERF57Neutral
FR:ALNOV45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | EUR 10.70B | 23.07 | 11.01% | 1.08% | -3.18% | 22.52% | |
| 58Neutral | EUR 259.38M | 37.71 | 3.89% | ― | 6.28% | 204.56% | |
| 57Neutral | EUR 15.04B | 28.49 | 14.81% | 0.84% | 3.38% | 28.21% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | EUR 31.50M | -0.75 | -159.70% | ― | 10.36% | 29.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALECR | Eurofins-Cerep SA | 15000.00 | -1100.00 | -6.83% | |
| FR:BIM | bioMerieux SA | 90.65 | -13.81 | -13.22% | |
| FR:ERF | Eurofins Scientific | 85.46 | 28.73 | 50.65% | |
| FR:ALNOV | Novacyt S.A. | 0.43 | 0.00 | 0.93% | |
| FR:ALERS | Eurobio-Scientific SA | 26.40 | 2.00 | 8.20% | |
| FR:ABLD | ABL Diagnostics SA | 2.40 | -0.23 | -8.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
